Cardiff Oncology Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
CRDF$0.80+5.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except par value)
| December 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $51,470 | $21,655 |
| Short-term investments | 40,276 | 53,168 |
| Accounts receivable and unbilled receivable | 773 | 288 |
| Prepaid expenses and other current assets | 2,535 | 2,301 |
| Total current assets | 95,054 | 77,412 |
| Property and equipment, net | 898 | 1,238 |
| Operating lease right-of-use assets | 1,169 | 1,708 |
| Other assets | 69 | 1,279 |
| Total Assets | $97,190 | $81,637 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $4,821 | $1,966 |
| Accrued liabilities | 7,897 | 7,783 |
| Operating lease liabilities | 710 | 691 |
| Total current liabilities | 13,428 | 10,440 |
| Operating lease liabilities, net of current portion | 813 | 1,458 |
| Total Liabilities | 14,241 | 11,898 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value, 20,000 shares authorized; 277 designated as Series A Convertible Preferred Stock; 61 shares outstanding at December 31, 2024 and December 31, 2023 with liquidation preference of $1,092 and $1,068 at December 31, 2024 and December 31, 2023, respectively | — | — |
| Common stock, $0.0001 par value, 150,000 shares authorized; 66,524 and 44,677 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 7 | 4 |
| Additional paid-in capital | 467,087 | 409,343 |
| Accumulated other comprehensive gain (loss) | 34 | (67) |
| Accumulated deficit | (384,179) | (339,541) |
| Total stockholders’ equity | 82,949 | 69,739 |
| Total liabilities and stockholders’ equity | $97,190 | $81,637 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.